Akeso Inc. has announced that the National Medical Products Administration (NMPA) has accepted its supplementary New Drug Application (sNDA) for ivonescimab, a PD-1/VEGF bispecific antibody, in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer. This marks the third accepted application for ivonescimab in China, building on previous submissions for its use in other forms of non-small cell lung cancer. The decision is based on positive outcomes from the Phase III HARMONi-6 study, which demonstrated the superiority of ivonescimab combined with chemotherapy over existing treatments. Ivonescimab is currently involved in several clinical trials worldwide, further establishing its role in global cancer immunotherapy.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。